Accelerate Diagnostics Stock News

Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler purchased 59,357 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an

Tables of the top insider purchases and sales filed with the SEC on 4/22/20, based on dollar value. Dollar values often do not equate with significance when it

Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have received an average rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. One equities r

Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Za

Accelerate Diagnostics Inc (NASDAQ:AXDX) shares rose 7.3% during mid-day trading on Wednesday following insider buying activity. The company traded as high as $9.88 and last traded at $9.67, approxima

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns from these stocks to buy.

Bank of New York Mellon Corp increased its holdings in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securi

The antimicrobial susceptibility testing market size has the potential to grow by USD 900.75 million during 2020-2024.

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, BidAskClub reports. A

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The b

Goldman Sachs Group Inc. grew its holdings in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 9.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 51,828 shares of the medica

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a l